JP2023132041A - Sleep quality improver and sleep quality-improving composition, daytime productivity improver and daytime productivity-improving composition, as well as concentration improver and concentration-improving composition - Google Patents

Abstract

To provide a sleep quality improver and a sleep quality-improving composition having excellent sleep quality-improving effect and high safety, to provide a daytime productivity improver and a daytime productivity-improving composition having excellent daytime productivity-improving effect and high safety, and to provide a concentration improver and a concentration improving-composition having excellent concentration-improving effect and high safety.SOLUTION: Provided are a sleep quality improver, a daytime productivity improver, or a concentration improver containing a compound represented by structural formula (1); and a sleep quality-improving composition containing the sleep quality improver, a daytime productivity-improving composition containing the daytime productivity improver, or a concentration improving composition containing the concentration improver.SELECTED DRAWING: None

Description

The present invention relates to a sleep quality improver and a composition for improving sleep quality, a daytime productivity improver and a composition for improving daytime productivity, and a concentration improver and a composition for improving concentration.

Humans spend approximately one-third of their lives sleeping, and sleep is considered the most important act for humans. However, in modern society, many people complain of sleep deprivation and insomnia due to disturbances in their daily rhythms, stress, lack of exercise, and the like.
Additionally, the quality of sleep declines with age. Therefore, as the number of elderly people increases, it is expected that the number of elderly people with poor sleep quality will increase in the future.
The quality of sleep is affected by various factors such as physical factors, psychological factors, pharmacological factors, environmental factors, etc. Generally, people have difficulty falling asleep, have trouble falling asleep, and wake up many times during the night. It induces mid-way awakening, early awakening where you wake up early in the morning, and poor sleep where you don't feel like you slept well. Poor sleep quality not only leads to serious diseases such as myocardial infarction and cerebral infarction, but also reduces productivity and concentration due to daytime sleepiness and fatigue, which can lead to serious accidents. This is an important issue.

So far, as a technique for improving sleep quality, sleep quality improving agents containing delphinidin-3-rutinoside, cyanidin-3-rutinoside, or a combination thereof as active ingredients have been proposed (for example, see Patent Document 1). .

However, it has the effect of improving sleep quality, improving daytime productivity, and improving concentration, and is highly safe, so it is used as an ingredient in foods and drinks, pharmaceuticals, research reagents, etc. There is still a strong demand for new materials that can be widely used, and the current situation is that prompt development is required.

JP2021-169441A

An object of the present invention is to solve the problems in the conventional art and to achieve the following objects. That is, an object of the present invention is to provide a sleep quality improving agent and a sleep quality improving composition that have an excellent sleep quality improving effect and are highly safe.
Another object of the present invention is to provide a daytime productivity improving agent and a daytime productivity improving composition that have an excellent daytime productivity improving effect and are highly safe.
Another object of the present invention is to provide a concentration improving agent and a concentration improving composition that have an excellent concentration improving effect and are highly safe.

As a result of extensive studies by the present inventors in order to solve the above problems, we found that the compound represented by the following structural formula (1) has an excellent effect of improving sleep quality, improving daytime productivity, and improving concentration. It has been found that it has a strength-enhancing effect, is highly safe, and is useful for improving sleep quality, daytime productivity, and concentration.

The present invention is based on the above findings of the present inventors, and means for solving the above problems are as follows. That is,
<1> A sleep quality improving agent characterized by containing a compound represented by the following structural formula (1).
<2> A composition for improving sleep quality characterized by containing the sleep quality improving agent according to <1> above.
<3> A daytime productivity improver characterized by containing a compound represented by the following structural formula (1).
<4> A composition for improving daytime productivity, characterized by containing the daytime productivity improving agent according to <3> above.
<5> A concentration improver characterized by containing a compound represented by the following structural formula (1).
<6> A composition for improving concentration characterized by containing the concentration improving agent according to <5> above.

According to the sleep quality improving agent and sleep quality improving composition of the present invention, it is possible to solve the above-mentioned problems in the past, achieve the above-mentioned objectives, have an excellent sleep quality-improving effect, and be safe. A sleep quality improving agent and a sleep quality improving composition with high performance can be provided.
According to the daytime productivity improving agent and the daytime productivity improving composition of the present invention, the above-mentioned problems in the past can be solved and the above-mentioned objectives can be achieved, and the daytime productivity improving effect is excellent. It is possible to provide a daytime productivity improving agent and a daytime productivity improving composition that have the following properties and are highly safe.
According to the concentration improver and composition for improving concentration of the present invention, it is possible to solve the above-mentioned problems in the past, achieve the above-mentioned objectives, have an excellent concentration-enhancing effect, and be highly safe. Concentration improvers and compositions for improving concentration can be provided.

FIG. 1 is a diagram showing the results of measuring the mid-wake-up time in Test Example 1. FIG. 2A is a diagram showing the results of measuring the function of the entire autonomic nervous system in a group ingesting a food (test food) containing the compound represented by structural formula (1) in Test Example 1. FIG. 2B is a diagram showing the results of measuring the function of the entire autonomic nervous system in a group ingesting food not containing the compound represented by structural formula (1) (control food) in Test Example 1.

(Sleep quality improver, daytime productivity improver, and concentration improver)
The sleep quality improving agent of the present invention contains a compound represented by the following structural formula (1) as an active ingredient, and further contains other ingredients as necessary.
The daytime productivity improver of the present invention contains a compound represented by the following structural formula (1) as an active ingredient, and further contains other ingredients as necessary.
The concentration improver of the present invention contains a compound represented by the following structural formula (1) as an active ingredient, and further contains other ingredients as necessary.

In this specification, improving the quality of sleep refers to improving the state of having difficulty waking up (feeling unwell immediately after waking up) to a good state or approaching a good state, and improving the state of not feeling well-drowsed upon waking up to the state of not feeling well-drowsed upon waking up. It means to be in a certain state or to get close to a certain state, and to shorten the period of waking up during the night.

In this specification, improving daytime productivity refers to increasing overall performance during the day, changing the state of being unable to maintain concentration during the day to being able to maintain it for a longer period of time, or increasing the ability to concentrate for a longer period of time. It refers to creating a state that can be sustained, increasing the overall function of the autonomic nervous system during the day, or increasing autonomic nervous activity.

As used herein, improving concentration refers to changing a state in which concentration cannot be sustained to a state in which it can be sustained for a long time, or a state in which it can be sustained for a longer period of time.

The compound represented by the structural formula (1) has an excellent effect of improving sleep quality, improving daytime productivity, and improving concentration, and a sleep quality improving agent; It has not been previously known that it is useful as a daytime productivity improver or a concentration improver, and this is a new finding by the present inventors.

<Compound represented by structural formula (1)>
The name of the compound represented by the following structural formula (1) is 3-(4-hydroxy-3-methoxyphenyl)propionic acid (English name: 3-(4-Hydroxy-3-methoxyphenyl)propionic acid) (hereinafter referred to as " (sometimes referred to as HMPA).

The compound represented by the structural formula (1) is a known compound, and a commercially available product may be used, or one extracted from a plant or the like may be used.

The content of the compound represented by the structural formula (1) in the sleep quality improving agent, daytime productivity improving agent, and concentration improving agent of the present invention is not particularly limited, and may be determined as appropriate depending on the purpose. You can choose.
The sleep quality improving agent, daytime productivity improving agent, and concentration improving agent may consist only of the compound represented by the structural formula (1).

<Other ingredients>
The other ingredients are not particularly limited as long as they do not impair the effects of the present invention, and are appropriately selected depending on the usage form of the sleep quality improver, daytime productivity improver, and concentration improver. For example, excipients, moisture-proofing agents, preservatives, fortifying agents, thickeners, emulsifiers, antioxidants, sweeteners, acidulants, seasonings, colorants, fragrances, whitening agents, humectants, oil-based ingredients, ultraviolet absorbers, surfactants, thickeners, alcohols, powder ingredients, coloring agents, aqueous ingredients, water, skin nutrients, etc. These may be used alone or in combination of two or more.

The content of the other components in the sleep quality improving agent, daytime productivity improving agent, and concentration improving agent is not particularly limited and can be appropriately selected depending on the purpose.

<Application>
The use of the sleep quality improving agent, daytime productivity improving agent, and concentration improving agent is not particularly limited and can be appropriately selected depending on the purpose, such as pharmaceuticals, quasi-drugs, Examples include food and drink.
The sleep quality improving agent has an excellent sleep quality improving effect and is highly safe, so it can be suitably used, for example, as an active ingredient of the sleep quality improving composition described below.
The daytime productivity improving agent has an excellent daytime productivity improving effect and is highly safe, so it can be suitably used, for example, as an active ingredient in a composition for improving daytime productivity described below. I can do it.
The concentration improving agent has an excellent concentration improving effect and is highly safe, so it can be suitably used, for example, as an active ingredient in a composition for improving concentration described below.

The sleep quality improving agent, daytime productivity improving agent, and concentration improving agent of the present invention are preferably applied to humans, but as long as the effects are exerted, they may also be applied to non-humans. It can also be applied to animals (eg, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.).

The usage of the sleep quality improving agent, daytime productivity improving agent, and concentration improving agent is not particularly limited and can be appropriately selected depending on the purpose, such as oral, parenteral, external use, etc. Examples include the usage of

The use site, usage method, and dosage form of the sleep quality improving agent, daytime productivity improving agent, and concentration improving agent can be appropriately selected depending on the purpose of use.

The sleep quality improving agent, daytime productivity improving agent, and concentration improving agent are prepared in powder form according to a conventional method using a pharmaceutically acceptable carrier such as dextrin or cyclodextrin, or any other auxiliary agent. It can be formulated into any dosage form such as granules, tablets, and liquids. In this case, as the auxiliary agent, for example, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring agent, etc. can be used.
The sleep quality improving agent, the daytime productivity improving agent, and the concentration improving agent may be used in combination with other compositions (e.g., a composition for improving sleep quality, a composition for improving daytime productivity, and a concentration improving agent described below). In addition to being used in parenteral preparations such as injections, drops, and suppositories, ointments, eye drops, external liquids, and patches, etc. You can also do it.

There are no particular restrictions on how to use the sleep quality improver, daytime productivity improver, and concentration improver, such as the amount, period of use, and interval of use, and they can be selected as appropriate depending on the purpose. can.

In addition, the sleep quality improving agent of the present invention has an effect of improving sleep quality, the daytime productivity improving agent of the present invention has a daytime productivity improving effect, and the concentration improving agent of the present invention has a concentration improving effect. It can also be used as a reagent for mechanistic studies.

(Composition for improving sleep quality, composition for improving daytime productivity, and composition for improving concentration)
The composition for improving sleep quality of the present invention contains the sleep quality improving agent of the present invention, and further contains other components as necessary.
The composition for improving daytime productivity of the present invention contains the daytime productivity improving agent of the present invention, and further contains other components as necessary.
The composition for improving concentration of the present invention contains the concentration improver of the present invention, and further contains other components as necessary.

<Sleep quality improver, daytime productivity improver, and concentration improver>
The sleep quality improving agent is the sleep quality improving agent of the present invention described above.
The daytime productivity improver is the daytime productivity improver of the present invention described above.
The concentration improver is the concentration improver of the present invention described above.

The content of the sleep quality improving agent in the sleep quality improving composition is not particularly limited and can be adjusted as appropriate depending on the form of the sleep quality improving composition. The amount of the compound represented by 1) is preferably 0.0001% by mass to 20% by mass, more preferably 0.0001% by mass to 10% by mass. The sleep quality improving composition may consist only of the sleep quality improving agent.

The content of the daytime productivity improving agent in the daytime productivity improving composition is not particularly limited, and can be adjusted as appropriate depending on the form of the daytime productivity improving composition. However, the amount of the compound represented by the structural formula (1) is preferably 0.0001% by mass to 20% by mass, more preferably 0.0001% by mass to 10% by mass. The composition for improving daytime productivity may consist only of the daytime productivity improving agent.

The content of the concentration improver in the composition for improving concentration is not particularly limited and can be adjusted as appropriate depending on the form of the composition for improving concentration. The amount of the compound expressed is preferably 0.0001% to 20% by weight, more preferably 0.0001% to 10% by weight. The composition for improving concentration may consist only of the concentration improving agent.

<Other ingredients>
Other ingredients in the composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration are not particularly limited. The composition for improving productivity and the composition for improving concentration can be selected as appropriate depending on the usage form, for example, the above-mentioned sleep quality improving agent, daytime productivity improving agent, and concentration improving agent. Other ingredients similar to those listed in the section above may be mentioned. These may be used alone or in combination of two or more.

The content of the other components in the composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration is not particularly limited and may be appropriately selected depending on the purpose. Can be done.

<Aspects>
The composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration are not particularly limited and can be appropriately selected depending on the purpose. , quasi-drugs, food and beverages, etc.
The composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration of the present invention can be used on a daily basis, and the active ingredient is the structural formula (1) ) can exhibit various physiologically active effects extremely effectively, including improving sleep quality, improving daytime productivity, and improving concentration.

The composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration of the present invention are preferably applied to humans, but their respective effects are not effective. It can also be applied to animals other than humans (for example, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as it is suitable.

The usage of the composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration of the present invention is not particularly limited and can be appropriately selected depending on the purpose, such as , oral, parenteral, and external administration, but oral administration is preferred.

Examples of the oral composition include the above-mentioned oral preparations and food and drink products. Here, food and beverages refer to foods that have little risk of harming human health and are ingested orally or through gastrointestinal administration in normal social life, and are administratively classified foods, drugs, and quasi-drugs. It is not limited to such categories. Therefore, the above-mentioned foods and drinks include general foods that are orally ingested, health foods (functional foods and drinks), foods with health claims (foods for specified health uses, foods with nutritional function claims, foods with functional claims), quasi-drugs, and pharmaceuticals. This term refers to a wide range of food and beverages that make up food and beverages.

The type of the composition for oral use is not particularly limited and can be appropriately selected depending on the purpose, such as tea drinks, soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, alcoholic drinks, Beverages such as coffee drinks and coffee-infused soft drinks (including concentrated stock solutions and powders for preparation of these beverages); Frozen desserts such as ice cream, ice sherbet, and shaved ice; Soba, udon, Harusame, gyoza skin, shumai skin, Noodles such as Chinese noodles and instant noodles; Candy, candy, gum, chocolate, tablets, snack foods, biscuits, jelly, jam, cream, baked goods, bread and other confectionery; Crab, salmon, clams, tuna, sardines, shrimp , bonito, mackerel, whale, oyster, saury, squid, red clam, scallop, abalone, sea urchin, salmon roe, tokobushi, and other marine products; fish cake, ham, sausage, and other processed marine and livestock products; processed milk, fermented milk, and other dairy products ; Fats and fat processed foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressing; Seasonings such as sauces and sauces; Curry, stew, oyakodon, rice porridge, rice porridge, Chinese rice bowl, katsudon, Retort pouch foods such as tempura bowls, eel bowls, hayashi rice, oden, marbodorf, beef bowls, meat sauce, egg soup, omelette rice, gyoza, shumai, hamburgers, and meatballs; side dishes such as salads and pickles; various forms of health, beauty, and nutrition Supplementary foods: Pharmaceuticals and quasi-drugs such as tablets, powders, capsules, granules, extracts, syrups, drinks, troches, and gargles; Oral products used in the oral cavity, such as mouth fresheners and anti-halitosis agents. Examples include refreshing agents and toothpaste.

There are no particular restrictions on the method for producing the composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration. It can be appropriately selected depending on the usage form of the composition for improving sexual ability and the composition for improving concentration.

There are no particular restrictions on the usage amount, usage period, usage interval, etc. of the composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration, and they can be selected as appropriate depending on the purpose. can do.

As described above, the sleep quality improving agent and the sleep quality improving composition of the present invention have an excellent sleep quality improving effect.
Therefore, the present invention also relates to a method for improving sleep quality, which comprises administering to an individual at least one selected from the group consisting of the sleep quality improving agent and the composition for improving sleep quality.

As described above, the daytime productivity improving agent and the daytime productivity improving composition of the present invention have an excellent daytime productivity improving effect.
Therefore, the present invention provides an improvement in daytime productivity characterized by administering to an individual at least one selected from the group consisting of the daytime productivity improving agent and a composition for improving daytime productivity. It also relates to methods.

As described above, the concentration improving agent and concentration improving composition of the present invention have an excellent concentration improving effect.
Therefore, the present invention also relates to a method for improving concentration, which comprises administering to an individual at least one selected from the group consisting of the above-mentioned concentration improver and a composition for improving concentration.

Test examples and formulation examples of the present invention will be described below, but the present invention is not limited to these test examples and formulation examples.

(Test example 1)
A clinical test of the compound represented by the structural formula (1) was conducted as follows.
・Study Randomized double-blind placebo-controlled comparative study ・Subjects 30 healthy adult men and women aged 40 to under 65 (15 people per group x 2 groups)
・ Method Actibody ^TM RB 100 mg capsule (manufactured by Maruzen Pharmaceutical Co., Ltd., 23 mg/day intake of the compound represented by the above structural formula (1)) (hereinafter sometimes referred to as "test food intake group"), or a placebo (hereinafter sometimes referred to as the "control food intake group") for 4 weeks.
・Evaluation items (A) Questionnaire survey (pre-intake test, 4th week test)
(B) Evaluation of sleep quality (mid-way awakening time) using a wristwatch-type activity meter (Silmee ^TM W22) (during the intake period)
Evaluation at the start of intake and the 4th week of intake using the average value for one week (C) Autonomic nerve activity evaluation using a wristwatch-type activity meter (Silmee ^TM W22) (during the intake period)
Evaluation based on the weekly average value at the start of intake and 4th week of intake

<Results>
[(A) Questionnaire survey-1]
The subjects were asked to rate whether their overall performance on their workdays over the past four weeks was good or bad, with 0 points being the worst and 10 points being the best. We asked them to answer on an 11-point scale with 10 points.
As a result, in the test food intake group, the test before intake was 6.9 ± 0.4 (mean ± standard error, hereinafter the same), and the test after 4 weeks of intake was 7.3 ± 0. 4". On the other hand, in the control food intake group, the test before intake was 6.5±0.4, and the test 4 weeks after intake was 6.6±0.3. In the test food intake group, it was confirmed that the evaluation score significantly increased compared to the control food intake group in the test after 4 weeks of intake (Mann-Whitney U test).

[(A) Questionnaire survey-2]
The subject was asked to rate whether or not he or she was unable to maintain concentration, with 7 points being the worst (applicable) and 1 point being the best (not applicable). We asked them to answer on a 7-point scale.
As a result, in the test food intake group, the test before intake was 2.6 ± 0.3 (mean ± standard error, hereinafter the same), and the test after 4 weeks of intake was 2.3 ± 0. 4". On the other hand, in the control food intake group, the test before intake was ``2.6±0.3'', and the test after 4 weeks of intake was ``3.1±0.4''. In the test food intake group, it was confirmed that the evaluation score significantly decreased compared to the control food intake group in the change value from the pre-consumption test in the 4th week of intake test (Mann-Whitney U test). .

[(A) Questionnaire survey-3]
The subjects were asked whether they felt "uncomfortable after waking up" or not, with "7" being the worst rating (feeling) and "1" being the best rating (not feeling). The respondents answered on a 7-point scale ranging from 1 to 7 points.
As a result, in the test food intake group, the test before intake was "3.0 ± 0.4"("mean value ± standard error", hereinafter the same), and the test after 4 weeks of intake was "2.5 ± 0. 2”. On the other hand, in the control food intake group, the test before intake was ``2.1±0.4'', and the test after 4 weeks of intake was ``2.7±0.3''. In the test food intake group, it was confirmed that the evaluation score significantly decreased compared to the control food intake group in the change value from the pre-consumption test in the 4th week of intake test (Mann-Whitney U test). .

[(A) Questionnaire survey-4]
Subjects were given a score of 1 to 7, with 7 being the worst rating (feeling) and 1 being the best rating (not feeling), as to whether they felt ``I don't feel like I had a deep sleep when I woke up.'' They were asked to answer on a seven-point scale.
As a result, in the test food intake group, the test before intake was 3.1 ± 0.4 (mean ± standard error, hereinafter the same), and the test after 4 weeks of intake was 2.8 ± 0. 3". On the other hand, in the control food intake group, the test before intake was 3.4±0.4, and the test 4 weeks after intake was 3.6±0.3. In the test food intake group, it was confirmed that the evaluation score was significantly decreased compared to the control food intake group in the test after 4 weeks of intake (Mann-Whitney U test).

[(B) Evaluation of sleep quality (mid-wake time) using a wristwatch-type activity meter]
Figure 1 shows the results of measuring mid-way awakening time, which is related to sleep quality, using a wristwatch-type activity meter.
In FIG. 1, the vertical axis represents the change in mid-way awakening time from the start of the intake in the fourth week of intake, and the horizontal axis represents each food intake group. Moreover, "□" represents the results for the test food intake group, and "■" represents the results for the control food intake group.
As shown in FIG. 1, during the fourth week of intake, it was confirmed that the mid-morning awakening time was shorter in the test food intake group compared to the control food intake group.

[(C) Autonomic nerve activity evaluation using a wristwatch-type activity meter]
The results of measuring the function of the entire autonomic nervous system using a wristwatch-type activity meter are shown in FIG. 2A (test food intake group) and FIG. 2B (control food intake group).
The overall function of the autonomic nervous system is determined by frequency analysis based on data acquired from the acceleration sensor of a wristwatch-type activity monitor, and the total power value of the low-frequency wave component (LF) and high-frequency wave component (HF) of the spectrum. (Total power; an index of the overall function of the autonomic nervous system) was calculated.
In Figures 2A and 2B, the vertical axis represents the measured value (total power) of the function of the entire autonomic nerve function, and the horizontal axis represents the time of day (0-6:0-6:00, 6-12:6:00-12:00). , 12-18: 12-18 o'clock, 18-24: 18-24 o'clock). Further, "●" indicates the results at the start of intake, and "■" indicates the results after the fourth week of intake.
As shown in FIGS. 2A and 2B, in the test food intake group, the activity of the autonomic nerves as a whole during the day (6:00 to 18:00) was higher in the 4th week of intake compared to the time when intake started. On the other hand, in the control food intake group, no difference was observed in autonomic nerve activity during the day (6:00 to 18:00) between the start of intake and the 4th week of intake.

(Combination example 1)
Tablets having the following composition were manufactured by a conventional method.
- Compound represented by the above structural formula (1) 5.0 mg
・Dolomite 83.4mg
(Contains 20% calcium and 10% magnesium)
・Casein phosphopeptide 16.7mg
・Vitamin C 33.4mg
・ Maltitol 136.8mg
・Collagen 12.7mg
・Sucrose fatty acid ester 12.0mg

(Combination example 2)
An oral liquid preparation having the following composition was produced by a conventional method.
<Composition in 1 ampoule (100 mL per bottle)>
- Compound represented by the above structural formula (1) 0.3% by mass
・Sorvit 12.0% by mass
・Sodium benzoate 0.1% by mass
・Fragrance 1.0% by mass
・Calcium sulfate 0.5% by mass
・Remaining purified water

(Combination example 3)
A coffee beverage having the following composition was produced by a conventional method.
- Compound represented by the above structural formula (1) 0.1% by mass
・Coffee extract (L (lightness) = 20, Brix = 3) 40.0% by mass
・Maltitol 2.0% by mass
- Appropriate amount of fragrance - Remaining water

(Combination example 4)
Capsules having the following composition were manufactured by a conventional method. Note that a No. 1 hard gelatin capsule was used as the capsule.
<Composition in 1 capsule (1 tablet 200mg)>
- Compound represented by the above structural formula (1) 30.0 mg
・Corn starch 70.0mg
・Lactose 80.0mg
・Calcium lactate 10.0mg
・Hydroxypropylcellulose (HPC-L) 10.0mg

Claims (6)

A sleep quality improving agent characterized by containing a compound represented by the following structural formula (1).
A composition for improving sleep quality, comprising the sleep quality improving agent according to claim 1. A daytime productivity improver comprising a compound represented by the following structural formula (1).
A composition for improving daytime productivity, comprising the daytime productivity improving agent according to claim 3. A concentration improving agent characterized by containing a compound represented by the following structural formula (1).
A composition for improving concentration, comprising the concentration improving agent according to claim 5.